TRINETRA › Sectors › Healthcare
Dr. Reddy's Laboratories Limited (DRREDDY) — share price, P/E and fundamentals
Dr. Reddy's Laboratories Limited (NSE: DRREDDY) closed at ₹1,352.00 on 30 Oct 2026, +7.7% over one year, against a 52-week range of ₹1,101.00 – ₹1,414.90.
In the quarter ended 30 Sept 2026 (consolidated, filed 23 Oct 2026) it reported revenue of ₹8,698 cr and net profit of ₹925 cr, a 10.6% net margin; revenue fell 1.5% and profit fell 28.9% year on year.
On four consecutive filed quarters its trailing P/E is 40.3; since 9 May 2025 its own P/E has ranged from 17.0 to 40.2 (median 19.1), and today's reading is higher than 100% of those 365 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 9.5%, ROCE 12.9%, debt-to-equity 0.15, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 27% of 63 sector peers; PBT margin higher than 29% of 63 sector peers; ROE higher than 24% of 63 sector peers.
Key figures
| Last close | ₹1,352.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +12.6% / +2.6% / +7.7% |
| 52-week low – high | ₹1,101.00 – ₹1,414.90 |
| Market capitalisation | ₹1,12,892 cr |
| Trailing P/E | 40.3 |
| Price / book | 2.91 |
| EV / EBITDA | 19.2 |
| Earnings yield | 2.5% |
| TTM EPS | ₹33.53 |
| TTM net profit | ₹2,800 cr |
| Quarter revenue | ₹8,698 cr |
| Quarter net profit | ₹925 cr |
| Net margin | 10.6% |
| Revenue growth (YoY) | -1.5% |
| Profit growth (YoY) | -28.9% |
| Return on equity | 9.5% |
| ROCE | 12.9% |
| Debt / equity | 0.15 |
| Current ratio | 1.93 |
| Free cash flow | ₹-147 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹199.0 cr |
Against Healthcare peers
| Metric | DRREDDY | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.63 | 12.89 | 27 |
| PBT margin | 14.20 | 17.68 | 29 |
| ROE | 9.53 | 13.87 | 24 |
| ROCE | 12.89 | 17.26 | 24 |
| Debt / equity | 0.15 | 0.11 | 58 |
| FCF margin | -0.87 | 2.08 | 50 |
| Cash conversion | 0.32 | 1.25 | 7 |
| Trailing P/E | 40.32 | 43.26 | 42 |
Questions
What is the P/E ratio of Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited's trailing P/E is 40.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 9 May 2025 its P/E has ranged 17.0–40.2.
What were Dr. Reddy's Laboratories Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Dr. Reddy's Laboratories Limited reported revenue of ₹8,698 cr and net profit of ₹925 cr (consolidated), filed with the exchange on 23 Oct 2026.
What is Dr. Reddy's Laboratories Limited's ROE?
Return on equity is 9.5% based on the balance sheet dated 30 Sept 2026.
Does Dr. Reddy's Laboratories Limited have debt?
Debt-to-equity is 0.15 on the balance sheet dated 30 Sept 2026.
What is DRREDDY's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, DRREDDY traded between ₹1,101.00 and ₹1,414.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.